Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Olomorasib · LY-3537982

Small molecule · Inhibitor of KRAS G12C (KRAS) · developed by ELI LILLY &

Phase 3 Most advanced trial
LLY Developer

What is Olomorasib?

Olomorasib is an orally available small-molecule inhibitor of KRAS G12C, a common oncogenic mutation. It selectively targets KRAS G12C mutant-dependent signaling to inhibit tumor cell growth, proliferation, invasion, and metastasis. It is studied in non-small-cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY-3537982
Drug type
Small molecule
Targets
KRAS G12C (KRAS)
Mechanism
Inhibitor of KRAS G12C (KRAS)
Pathways
MAPK/ERK, PI3K/Akt
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
C2VJ83PSN7

Conditions studied

Carcinoma, Non-Small-Cell Lung

Other drugs acting on KRAS

Sotorasib FDA approved AN9025 Phase 1 ARV-806 Phase 1/2 Calderasib Phase 3 Elironrasib Phase 1/2 ERAS-0015 Phase 1 Zoldonrasib Phase 1/2

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Olomorasib

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.